Biogen Closing Gap On Amevive Reimbursement: Pre-Authorization At 30%
Executive Summary
The percentage of Amevive patients needing prior authorization for the psoriasis biologic has shrunk to 30%, Biogen Idec CEO Jim Mullen told investors Jan. 12 at the J.P. Morgan health care cconference in San Francisco